BioSig Technologies Announces Acceptance of Paper for the 40th International Conference of the IEEE Engineering in Medicine and Biology Society
Paper regarding unipolar intracardiac signals as a parameter for catheter contact to be presented at EMBC ‘18 July 17-21 in Honolulu, Hawaii
Santa Monica, CA, May 09, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that its submission entitled, “Unipolar Intracardiac Signal Morphology as a Parameter for Catheter Contact Evaluation” was accepted as a 1-page paper for presentation at the 40th International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2018).
BioSig’s paper discusses a very important problem common for current electrophysiology (EP) studies: contact between catheter tip and myocardial tissue affects both the accuracy of cardiac maps and the efficacy of ablation energy delivery. Our findings suggest that the morphology of a unipolar signal obtained by using our PURE EP(TM) System can provide incremental information in contact evaluation.
“It is an honor for our findings to be accepted for presentation by the world’s largest professional organization for biomedical engineers. BioSig continues to collaborate with the best electrophysiologists in our field and strives toward advancing science. These findings can potentially lead to more effective ablation strategies, and ultimately, and more importantly, better outcomes for patients,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
About EMBC 2018
The IEEE Engineering in Medicine and Biology Society is hosting its 40th International Engineering in Medicine and Biology Conference in Honolulu, Hawaii from July 17-21, 2018 at the Hawaii Convention Center. The theme of the meeting is “Learning from the Past, Looking to the Future”, inspired by the 40th anniversary of the world’s largest international biomedical engineering meeting. Consistent with the theme, there will be plenary keynotes from leading industrial and academic scientists, who will give forward looking visions as well as historical perspectives on the field. A broad array of scientific tracks will cover diverse topics of cutting-edge research and innovation in biomedical engineering, healthcare technology R&D, translational clinical research, technology transfer and entrepreneurship, and biomedical engineering education. In addition to the high-profile keynotes, the conference program will feature mini symposia, workshops, invited sessions, oral and poster sessions, sessions for students and young professions, sessions for clinicians and entrepreneurs, and exhibits from vendors and universities.
About IEEE
The Institute of Electrical and Electronics Engineers (IEEE) is world's largest association of technical professionals with more than 420,000 members in over 160 countries around the world. Its objectives are the educational and technical advancement of electrical and electronic engineering, telecommunications, computer engineering and allied disciplines.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP(TM) System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Registration Statement on Form S-1 (File No. 333-223298), as declared effective on March 26, 2018, its Annual Report on Form 10-K/A filed with the SEC on March 26, 2018 and its Quarterly Report on Form 10-Q as filed with the SEC on May 4, 2018. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
Released May 9, 2018
